NLS Pharmaceutics AG
NLSP0.762USD
0.0000.00%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
3.16MMarket Cap
--P/E TTM
More Details of NLS Pharmaceutics AG Company
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.
NLS Pharmaceutics AG Info
Ticker SymbolNLSP
Company nameNewcelX AG
IPO dateJan 29, 2021
CEOZwyer (Alexander)
Number of employees1
Security typeOrdinary Share
Fiscal year-endJan 29
AddressThe Circle 6
CityZUERICH
Stock exchangeNASDAQ Capital Market Consolidated
CountrySwitzerland
Postal code8058
Phone41445122150
Websitehttps://nlspharma.com/
Ticker SymbolNLSP
IPO dateJan 29, 2021
CEOZwyer (Alexander)
Company Executives of NLS Pharmaceutics AG
Name
Name/Position
Position
Shareholding
Change
Mr. Ronald Hafner
Mr. Ronald Hafner
Independent Chairman of the Board
Independent Chairman of the Board
438.17K
+129669.00%
Dr. Eric Konofal, M.D., Ph.D.
Dr. Eric Konofal, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
48.53K
+48528.00%
Mr. Gian-Marco Rinaldi
Mr. Gian-Marco Rinaldi
Independent Director
Independent Director
12.40K
+12399.00%
Ms. Florence Allouche Aknin
Ms. Florence Allouche Aknin
Independent Director
Independent Director
3.00K
+3005.00%
Mr. Alexander Zwyer
Mr. Alexander Zwyer
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Cindy Rizzo
Ms. Cindy Rizzo
Investor Relations
Investor Relations
--
--
Ms. Nicole Fernandez-mcgovern
Ms. Nicole Fernandez-mcgovern
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Olivier Samuel
Mr. Olivier Samuel
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Ronald Hafner
Mr. Ronald Hafner
Independent Chairman of the Board
Independent Chairman of the Board
438.17K
+129669.00%
Dr. Eric Konofal, M.D., Ph.D.
Dr. Eric Konofal, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
48.53K
+48528.00%
Mr. Gian-Marco Rinaldi
Mr. Gian-Marco Rinaldi
Independent Director
Independent Director
12.40K
+12399.00%
Ms. Florence Allouche Aknin
Ms. Florence Allouche Aknin
Independent Director
Independent Director
3.00K
+3005.00%
Mr. Alexander Zwyer
Mr. Alexander Zwyer
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Cindy Rizzo
Ms. Cindy Rizzo
Investor Relations
Investor Relations
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Jan 3
Updated: Sat, Jan 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sarl (League Jann)
21.24%
Revel (Michel)
20.22%
Hafner (Ronald)
9.61%
Clover Wolf Capital - Limited Partnership.
7.53%
Twito (Ronen)
5.41%
Other
35.99%
Shareholders
Shareholders
Proportion
Sarl (League Jann)
21.24%
Revel (Michel)
20.22%
Hafner (Ronald)
9.61%
Clover Wolf Capital - Limited Partnership.
7.53%
Twito (Ronen)
5.41%
Other
35.99%
Shareholder Types
Shareholders
Proportion
Individual Investor
60.24%
Corporation
7.53%
Holding Company
3.54%
Investment Advisor
1.32%
Hedge Fund
0.32%
Other
27.06%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
16
74.40K
1.63%
-243.54K
2025Q3
18
223.48K
5.21%
-129.02K
2025Q2
26
1.40M
38.90%
+507.92K
2025Q1
22
894.91K
48.25%
+498.74K
2024Q4
29
1.02M
51.68%
+526.99K
2024Q3
29
831.36K
56.13%
+285.14K
2024Q2
30
615.17K
76.38%
+216.04K
2024Q1
28
605.94K
63.12%
+266.33K
2023Q4
27
460.27K
50.03%
+88.87K
2023Q3
27
471.85K
51.33%
+97.30K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sarl (League Jann)
968.21K
21.24%
+760.29K
+365.68%
Oct 30, 2025
Revel (Michel)
921.89K
20.22%
+732.87K
+387.74%
Oct 30, 2025
Hafner (Ronald)
438.17K
9.61%
+129.67K
+42.03%
May 22, 2025
Clover Wolf Capital - Limited Partnership.
343.12K
7.53%
+343.12K
--
Oct 30, 2025
Twito (Ronen)
246.51K
5.41%
+246.51K
--
Oct 30, 2025
Alpha Capital Aktiengesellschaft
161.29K
3.54%
-85.71K
-34.70%
May 15, 2025
Grisard (Felix)
107.37K
2.36%
+107.37K
--
Oct 15, 2024
The Lind Partners, LLC
59.78K
1.31%
-43.75K
-42.26%
Dec 31, 2024
Konofal (Eric)
48.53K
1.06%
+48.53K
--
May 15, 2025
BVF Partners L.P.
14.37K
0.32%
-129.31K
-90.00%
Oct 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Sep 25, 2024
Merger
40→1
Sep 25, 2024
Merger
40→1
Sep 25, 2024
Merger
40→1
Sep 25, 2024
Merger
40→1
Date
Ex-dividend Date
Type
Ratio
Sep 25, 2024
Merger
40→1
Sep 25, 2024
Merger
40→1
Sep 25, 2024
Merger
40→1
Sep 25, 2024
Merger
40→1
